PharmaChild

Juvenile idiopathic arthritis (JIA) is the most common chronic paediatric rheumatic disease and an important cause of short and long-term disability and quality of life impairment. Methotrexate (MTX) is the second line agent of first choice for the treatment of children with polyarticular JIA who do not respond to NSAIDs.
Patients with JIA who do not respond or are intolerant to MTX are candidates for the treatment with biologic agents such as etanercept, infliximab, adalimumab, abatacept and others currently in development. However, little information exists on the long term safety of these agents that are currently being used in children with JIA.

Pharmachild is a pharmacovigilance projects which aims at observing children with JIA for 3-10 years undergoing treatment with MTX or biologic agents in order to collect moderate, severe or serious adverse events occurred.

This project will be conducted by the participating centres of the more than 50 countries belonging to the Paediatric Rheumatology INternational Trials Organisation (PRINTO certified ISO 9001-2008, www.printo.it), or the Pediatric Rheumatology European Society (PRES at www.pres.org.uk).

More than 200 PRINTO centres worldwide have already expressed their interest in participating to the project.???Pharmachild is currently funded by the European Union (EU) within the FP7 framework (principal investigator Dr Nico Wulffraat, co-principal investigator Dr Nicolino Ruperto).

Contact
PRINTO
Istituto G. Gaslini, Universita’ di Genova
Pediatria II, Reumatologia
EULAR Centre of Excellence in Rheumatology 2008-2013
Largo Gaslini, 5
16147 Genova
ITALY

printo@ospedale-gaslini.ge.it

00-39-010-38-28-54 00-39-010-39-34-25
00-39-010-39-33-24 00-39-010-39-36-19


  
Login